<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Medicenna Therapeutics Corp — News on 6ix</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp</link>
<description>Latest news and press releases for Medicenna Therapeutics Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/medicenna-therapeutics-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f9a478dffbe2df130f9e.webp</url>
<title>Medicenna Therapeutics Corp</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp</link>
</image>
<item>
<title>Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-and-fondazione-melanoma-onlus-announce-presentation-on-neocyt-trial-at-asco-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-and-fondazione-melanoma-onlus-announce-presentation-on-neocyt-trial-at-asco-2026</guid>
<pubDate>Thu, 30 Apr 2026 11:30:00 GMT</pubDate>
<description>TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#x201C;Med...</description>
</item>
<item>
<title>Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-presents-positive-data-demonstrating-superior-safety-and-efficacy-potential-of-its-first-in-class-anti-pd-1-x-il-2-bifunctional-superkine-mdna113-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-presents-positive-data-demonstrating-superior-safety-and-efficacy-potential-of-its-first-in-class-anti-pd-1-x-il-2-bifunctional-superkine-mdna113-at-aacr-2026</guid>
<pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
<description>New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the ...</description>
</item>
<item>
<title>Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Tue, 14 Apr 2026 11:30:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...</description>
</item>
<item>
<title>Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-appoints-dr-nageatte-ibrahim-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-appoints-dr-nageatte-ibrahim-as-chief-medical-officer</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...</description>
</item>
<item>
<title>Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-present-preclinical-data-from-its-first-in-class-tumor-anchored-and-conditionally-activated-anti-pd-1-il-2-bifunctional-superkine-at-the-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-present-preclinical-data-from-its-first-in-class-tumor-anchored-and-conditionally-activated-anti-pd-1-il-2-bifunctional-superkine-at-the-aacr-annual-meeting-2026</guid>
<pubDate>Wed, 18 Mar 2026 11:30:00 GMT</pubDate>
<description>MDNA113 is a novel IL-13R&#x03B1;2 tumor-targeted and &#x201C;masked&#x201D; anti-PD-1-IL-2 Super...</description>
</item>
<item>
<title>Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-third-quarter-130900727</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-third-quarter-130900727</guid>
<pubDate>Fri, 13 Feb 2026 13:09:00 GMT</pubDate>
<description>Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data for MDNA11 demonstrates compelling activity in earlier-line expansion cohorts Among expansion cohorts treated with MDNA11 as a 2L or3L systemic treatment or as the next treatment following resistance to checkpoint therapy, MDNA11 demonstrated an objective response rate (“ORR”) of</description>
</item>
<item>
<title>Medicenna Announces Changes to Board Composition</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-announces-changes-board-composition-120000830</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-announces-changes-board-composition-120000830</guid>
<pubDate>Fri, 13 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company (the “Board”). “We are excited to welcome Mr. Richard Sutin and Mr. Angelos Georgakis to the Medicenna board of directors</description>
</item>
<item>
<title>Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-announces-key-program-123000061</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-announces-key-program-123000061</guid>
<pubDate>Thu, 15 Jan 2026 12:30:00 GMT</pubDate>
<description>Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer patients with no treatment options Among all efficacy-evaluable monotherapy patients comprising 18 different cancers (n=55), ORR was19% with MDNA11 as a 2L/3L treatment and 24% when MDNA11 was the next treatment post-ICI failure Based on these data, Medicenna plans to complete ABIL</description>
</item>
<item>
<title>Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-updates-mdna11-clinical-trial-results-at-the-esmo-io-congress-2025-further-bolstering-its-anti-tumor-activity-in-advanced-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-updates-mdna11-clinical-trial-results-at-the-esmo-io-congress-2025-further-bolstering-its-anti-tumor-activity-in-advanced-solid-tumors</guid>
<pubDate>Wed, 10 Dec 2025 12:30:00 GMT</pubDate>
<description>MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched f...</description>
</item>
<item>
<title>Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-to-host-a-live-webinar-with-qanda-to-discuss-updated-mdna11-clinical-data</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-to-host-a-live-webinar-with-qanda-to-discuss-updated-mdna11-clinical-data</guid>
<pubDate>Tue, 09 Dec 2025 22:04:30 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#...</description>
</item>
<item>
<title>Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-second-quarter-fiscal-2026-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-second-quarter-fiscal-2026-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society f...</description>
</item>
<item>
<title>Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-and-fondazione-melanoma-onlus-collaborate-to-advance-mdna11-before-first-line-therapy-in-a-randomized-neoadjuvant-combination-trial-neo-cyt-in-high-risk-surgically-resectable-stage-iii-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-and-fondazione-melanoma-onlus-collaborate-to-advance-mdna11-before-first-line-therapy-in-a-randomized-neoadjuvant-combination-trial-neo-cyt-in-high-risk-surgically-resectable-stage-iii-melanoma</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery...</description>
</item>
<item>
<title>Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-fondazione-melanoma-onlus-collaborate-120000612</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-fondazione-melanoma-onlus-collaborate-120000612</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe The NEO-CYT Study will evaluate MDNA11 as a neoadjuvant immunotherapy in earlier-stage melanoma patients whose immune systems are more amenable to immunotherapy and may be more likely to benefit from MDNA11 treatment Based on</description>
</item>
<item>
<title>Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/updated-mdna11-clinical-data-from-the-ability-1-study-to-be-presented-at-the-european-society-for-medical-oncology-esmo-immuno-oncology-congress-2025</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/updated-mdna11-clinical-data-from-the-ability-1-study-to-be-presented-at-the-european-society-for-medical-oncology-esmo-immuno-oncology-congress-2025</guid>
<pubDate>Thu, 23 Oct 2025 21:12:06 GMT</pubDate>
<description>TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#x201C;Medi...</description>
</item>
<item>
<title>Medicenna Therapeutics Announces Participation in Upcoming Conferences</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-announces-participation-in-upcoming-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-announces-participation-in-upcoming-conferences</guid>
<pubDate>Mon, 20 Oct 2025 11:00:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#...</description>
</item>
<item>
<title>ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/roth-to-host-4th-annual-healthcare-opportunities-conference-on-october-9-in-new-york-city</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/roth-to-host-4th-annual-healthcare-opportunities-conference-on-october-9-in-new-york-city</guid>
<pubDate>Wed, 01 Oct 2025 13:35:00 GMT</pubDate>
<description>NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (&#x201C;ROTH&#...</description>
</item>
<item>
<title>Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-to-participate-in-the-roth-4th-annual-healthcare-opportunities-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-to-participate-in-the-roth-4th-annual-healthcare-opportunities-conference</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#...</description>
</item>
<item>
<title>Medicenna Announces Results of Annual Meeting of Shareholders</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-announces-results-of-annual-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-announces-results-of-annual-meeting-of-shareholders</guid>
<pubDate>Thu, 25 Sep 2025 21:00:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...</description>
</item>
<item>
<title>Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-participate-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-to-participate-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
<pubDate>Fri, 05 Sep 2025 11:00:00 GMT</pubDate>
<description>TORONTO&#xA0;and&#xA0;HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...</description>
</item>
<item>
<title>Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-first-quarter-fiscal-2026-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/medicenna-therapeutics-corp/news/medicenna-therapeutics-reports-first-quarter-fiscal-2026-financial-results-and-operational-highlights</guid>
<pubDate>Fri, 01 Aug 2025 11:00:00 GMT</pubDate>
<description>Updated cash guidance provides runway into at least the middle of calendar 2026 Company r...</description>
</item>
</channel>
</rss>